THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Cornish, Virginia
Jafariyan, Amirhossein
Abstract
The disclosed subject matter provides for genetically modified cells, e.g., fungal cells, that autonomously generates and/or secretes one or more skin therapeutics, and methods of use thereof. In certain embodiments, the present disclosure provides genetically-engineered fungal cells that generate and secrete growth factors, protease inhibitors, cytokines and/or chemokines and methods of use thereof, e.g., for treating skin conditions.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
NEWSOUTH INNOVATIONS PTY LIMITED (Australia)
Inventor
Leong, Kam W.
Zhong, Yiling
Abstract
The anionic manganese oxide nanoparticle nucleic acid scavengers are biodegradable anionic scavengers with low cytotoxicity, which are able to scavenge (bind) cell-free nucleic acids (e.g., extracellular ssRNA, dsRNA, and unmethylated DNA), providing treatment for various medical conditions. The main component of the scavenger is manganese oxide, which may be synthesized by using a manganese compound (e.g., manganese acetate) and an acid (e.g., tannic acid) at high temperature (e.g., 100-150°C). Synthesis may be performed by mixing a manganese compound and an acid in water forming a mixture, which is stirred, heated, and allowed to cool. The anionic manganese oxide nanoparticles are extracted from the cooled mixture. The typical size of the resultant nanomaterials ranges from 30 to 100 nm; the zeta potential of the as-prepared nanomaterials is about -20 mV. The nanoparticles have various uses, including administration to a subject to treat inflammation or to treat cancer.
A61K 47/56 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (USA)
VANDERBILT UNIVERSITY (USA)
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventor
Kim, Jinho
Vunjak-Novakovic, Gordana
O'Neill, John D.
Pinezich, Meghan
Guenthart, Brandon A.
Mir, Seyed Mohammad
Chen, Jiawen
Bacchetta, Matthew
Abstract
A minimally invasive device, containing a pressure channel, camera, and optical fiber imaging probe, to measure the stiffness of tissues in vivo and ex vivo is disclosed. The device is inserted into a patient and navigated to a tissue of interest, where stiffness is evaluated by applying suction and measuring the elongation or by applying compression force and measuring the compression of the tissue. Biopsies can be taken for further analysis, or tissue can be removed using an ablation laser. Small fluorescent molecules or therapeutics can also be delivered for improved visualization and targeted treatment. As such, this technology may be used to evaluate the stiffness of biomaterials as well as tissues and organs that are difficult to access, allowing for simultaneous diagnosis, treatment, and excision of diseased tissues.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Sykes, Megan
Yang, Yong-Guang
Abstract
Provided herein are methods of xenotransplantation, for example, porcine to human transplantation. Also provided herein are extracellular vesicles ("EVs", e.g., exosomes) and compositions comprising the same, e.g. EVs expressing human CD47. Further provided herein are methods of making EVs and use thereof for xenotransplantation. In some aspects, the methods of xenotransplantation comprise steps of expressing human CD47 on xenografts.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Matsuda, Kazuko
Ambrosini, Grazia
Schwartz, Gary K.
Rai, Alex J.
Abstract
A method of preventing metastasis of a cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 35/04 - Antineoplastic agents specific for metastasis
6.
SYSTEMS AND METHODS FOR POWER CONVERSION WITH LC FILTER HAVING ADDITIONAL CAPACITOR
THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (USA)
Inventor
Preindl, Matthias
Zhou, Liwei
Eull, William-Michael
Jahnes, Matthew
Abstract
Systems and methods for a high-efficiency power converter incorporating a half-bridge topology with one or more an additional upper capacitor and a drain-source capacitor. The converter includes DC voltage terminals and a DC link capacitor coupled across a positive and negative DC terminal of the DC voltage terminals. The converter further includes a power switching element pair including a high side switch and a low side switch coupled together at a midpoint node. The converter further includes an LC filter having a switch-side inductor, a lower capacitor coupled between a second end of switch- side inductor and the negative DC terminal; and an upper capacitor coupled between the second end of the switch-side inductor and the positive DC terminal. The converter may further include drain-source capacitors coupled across the drain and source terminals of the switches.
H02M 1/08 - Circuits specially adapted for the generation of control voltages for semiconductor devices incorporated in static converters
H02M 1/084 - Circuits specially adapted for the generation of control voltages for semiconductor devices incorporated in static converters using a control circuit common to several phases of a multi-phase system
H02M 1/02 - Circuits specially adapted for the generation of grid-control or igniter-control voltages for discharge tubes incorporated in static converters
H02M 1/12 - Arrangements for reducing harmonics from ac input or output
H02M 1/14 - Arrangements for reducing ripples from dc input or output
H02M 1/16 - Means for providing current step on switching, e.g. with saturable reactor
7.
SYSTEMS AND METHODS FOR CONTROL OF ZERO-SEQUENCE STABILIZED POWER CONVERTERS
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Preindl, Matthias
Zhou, Liwei
Eull, William-Michael
Jahnes, Matthew
Abstract
Disclosed are implementations that include a power converter system including a non-isolated N-phase DC/AC power converter, for N = 1, with a DC voltage section and an N- phase AC voltage section, with the power converter including energy storage arrangements for each of three phases of the AC voltage section. The energy storage arrangements are commonly electrically coupled to the terminals of the DC voltage section. The system further includes a controller to control voltages at the energy storage arrangements, with the controller including one or more switching devices to control voltages at one or more terminals of the energy storage arrangements, and at least one model predictive control (MFC) module to generate control signaling, based on electrical operational characteristics of at least some of storage elements, to actuate the one or more switching devices to establish zero sequence voltage stabilization behavior at the terminals of the energy storage arrangements.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Preindl, Matthias
Zhou, Liwei
Eull, William-Michael
Jahnes, Matthew
Abstract
Disclosed are implementations that include a non-isolated power converter system comprising a filter including an inductor and a capacitor. The inductor of the filter includes a core portion and a winding portion. The core portion may include different shape core structures. The winding portion includes a winding embedded within a printed circuit board. The printed circuit board winding may include a litz wiring, and the printed circuit board having located thereon one or more of a controller or power switching elements.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Preindl, Matthias
Zhou, Liwei
Eull, William-Michael
Jahnes, Matthew
Abstract
Disclosed are implementations that include a power converter system and method including an N-phase power converter stage having to an alternating current (AC) side and a direct current (DC) side, with N > 1. The system and method further include an N-phase LC filter comprising one or more capacitors, wherein respective one or more neutral points of the one or more capacitors are electrically connected to a DC negative terminal of a DC source. A control system drives power switching elements of the N-phase power converter stage to convert received power and to output converted power. The control system drives the power switching elements using variable frequency soft switching at a frequency of at least 20 kHz. The power converter may have bidirectional operation to operate in a traction mode to drive a motor or a charging mode to charge a DC source.
H02M 7/02 - Conversion of ac power input into dc power output without possibility of reversal
H02M 1/12 - Arrangements for reducing harmonics from ac input or output
H02M 7/42 - Conversion of dc power input into ac power output without possibility of reversal
10.
CHARACTERIZATION OF POTENT AND BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SARS-COV-2, ITS VARIANTS, AND RELATED CORONAVIRUSES AND METHODS OF USE
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Ho, David D.
Huang, Yaoxing
Liu, Lihong
Nair, Manoj S.
Yu, Jian
Iketani, Sho
Abstract
The subject matter described herein relates to engineered monoclonal antibodies, derived from antibodies isolated from human patients, neutralizing a SARS-CoV-2 virus, its variants, or related coronaviruses.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Creusot, Remi J.
Firdessa Fite, Rebuma
Postigo Fernandez, Jorge
Abstract
This disclosure describes a nucleic acid construct that contains sequences for an Endotope construct, a STAT1c, and miR142 target sites. In one example, disclosed is composition comprising an Endotope construct and a STAT1 construct including a nucleic acid sequence encoding a constitutively active STAT1 (e.g. STAT1c), wherein the Endotope and the STAT1 constructs each include miR142 target sites. In alternative examples, disclosed is a single construct that includes the Endotope construct and STAT1 construct along with miR142 target sites. The nucleic acid constructs can be packaged into polycationic molecules or liposome to create nanoparticles for efficient cell transfection.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
12.
SYSTEMS, METHODS, AND COMPONENTS FOR RNA-GUIDED EFFECTOR RECRUITMENT
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Sternberg, Samuel Henry
Lampe, George Davis
King Davidson, Rebeca Teresa
Abstract
The present disclosure provides systems, kits, and methods provide systems and methods for recruiting one or more effector domains to a target nucleic acid and or modulating expression of a target gene in a cell utilizing an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) system. More particularly, the present disclosure provides systems comprising: an engineered CRISPR-Cas system or one or more nucleic acids encoding the engineered CRISPR-Cas system, wherein the CRISPR-Cas system comprises: at least one Cas protein (e.g., Cas6, Cas7, Cas5, Cas8 and/or Cas12k); a guide RNA (gRNA) complementary to at least a portion of the target nucleic acid sequence; and, optionally, at least one transposon-associated protein (e.g., TniQ, TnsC, TnsA, and/or TnsB).
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Sternberg, Samuel Henry
Lampe, George Davis
King Davidson, Rebeca Teresa
Chavez, Alejandro
Klompe, Sanne Eveline
Abstract
The present disclosure provides systems, kits, and methods for nucleic acid integration utilizing engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR-associated transposon (CRISPR-Tn) system. More particularly, the present disclosure provides systems comprising: an engineered CRISPR-Tn system or one or more nucleic acids encoding the engineered CRISPR-Tn system, wherein the CRISPR-Tn system comprises at least one or both of: a) at least one Cas protein (e.g., Cas6, Cas7, Cas5, and/or Cas8); and b) one or more transposon-associated proteins (e.g., TnsA, TnsB, TnsC, TnsD, and/or TniQ). The present disclosure also provides systems, kits, and methods for nucleic acid integration in a eukaryotic cell.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (USA)
Inventor
Gorbunova, Vera
Seluanov, Andrei
Suh, Yousin
Abstract
The present invention relates to an isolated nucleic acid molecule encoding a variant of sirtuin 6 (SIRT6) having at least 75% identity with sequence SEQ ID NO: 1, the variant having at least one mutation selected in the group comprising or consisting of a N308K substitution and a A313S substitution with respect to sequence SEQ ID NO: 1. The invention provides means for the regulation of ageing, and/or senescence, and/or lifespan in an individual. The invention further provides means for the repair of double strand breaks in a cell. Finally, the invention also provides means for the prevention and/or the treatment of an age-related disease.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Ho, David D.
Huang, Yaoxing
Nair, Manoj S.
Abstract
The subject matter disclosed herein relates to a recombinant spike (S) protein from the B.1.351.2-7 variant of the SARS-CoV-2 virus, the DNA and RNA nucleotide sequences encoding the recombinant B.1.351.2-7 spike protein, and engineered antibodies that bind the B.1.351.2-7 spike protein and neutralize the B.1.351.2-7 virus.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (USA)
Inventor
Clark, Samuel
Wengler, Kenneth
Horga Hernandez, Guillermo
Abstract
An exemplary system, method and computer-accessible medium for harmonizing neuromelanin (NM) data using combat directly on a NM database or using combat generated coefficients to harmonize future data can include, for example, receiving imaging information of a brain of the patient(s), from one MRI scanner, receiving imaging information of a brain of the patient(s), from a second MRI scanner and using combat to harmonize the data between scanners against a reference dataset. The Neuromelanin (NM) concentration of the patient(s) can then be determined based on the harmonized data. The NM concentration can be determined using a voxel-wise analysis procedure. The voxel-wise analysis procedure can be used to determine a topographical pattern(s) within a substantia nigra (SN) of the brain of the patient(s).
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
17.
OXA-IBOGAINE ANALOGUES FOR TREATMENT OF SUBSTANCE USE DISORDERS
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
HIGH POINT UNIVERSITY (USA)
Inventor
Sames, Dalibor
Hemby, Scott
Havel, Vaclav
Abstract
The present invention provides a method of treating a subject afflicted with a substance use disorder (SUD) comprising administering to the subject an effective amount of a compound having the structure: [STRUCTURE], or a pharmaceutically acceptable salt or ester thereof, wherein A, X1, X2, Y1-Y6 and R1-R4 are as defined in the specification, so as to thereby treat the subject afflicted with the substance use disorder (SUD).
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 25/00 - Drugs for disorders of the nervous system
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES IN THE CITY OF ALBANY (USA)
Inventor
Petrukhin, Konstantin
Racz, Boglarka
Varadi, Andras
Cioffi, Christopher L.
Muthuraman, Parthasarathy
Raja, Arun
Abstract
The present invention provides a pharmaceutical composition comprising the compound of any the present invention and a pharmaceutically acceptable carrier. The present invention provides a method for stabilizing TTR tetramers in a mammal comprising administering to the mammal an amount of a compound of the present invention or a composition of the present invention effective to stabilize TTR tetramers.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 275/03 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
19.
OXA-IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Sames, Dalibor
Havel, Vaclav
Bechand, Benjamin
Lankri, David
Abstract
The present invention provides a compound having the structure: [STRUCTURE}, wherein D,E,F,X1, X2 and R1-R14 are as defined herein; a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier; and a method of treating a subject afflicted with a substance use disorder, opioid withdrawal symptoms, a depressive disorder, a mood disorder, an anxiety disorder, Parkinson's disease, traumatic brain injury, a headache, a migraine, or of altering the psychological state or enhancing the effect of psychotherapy, comprising administering to the subject an effective amount of said compound or a pharmaceutically acceptable salt thereof.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 25/00 - Drugs for disorders of the nervous system
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Vardner, Jonathan
West, Alan
Banta, Scott
Abstract
A copper concentrate such as chalcopyrite is contacted with an aqueous solution includes acids and a reducing agent, such as vanadium (II) ions, chromium (II) ions, or tungstozincic acid (H6ZnW12O40). The aqueous solution reduces the copper in the copper concentrate, which can then dissolve into the solution for recovery therefrom, or precipitate out of solution as copper compounds or elemental copper for recovery in as a solid phase product. The solid phase product can then be isolated, dissolved, and further electrowinned to recover a copper product from the copper concentrate. Oxidized reducing agent can be recovered in an electrochemical device with ferrous iron reactants. Hydrometallurgical routes to convert copper concentrates to copper are potentially less expensive and less polluting than current pyrometallurgical processing and an advantageous response to environmental and economic pressures for increased copper production.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Iavarone, Antonio
Lasorella, Anna
Abstract
The subject matter disclosed herein relates to a method of treating glioblastoma (GBM) in a subject in need thereof, the method comprising determining one or more GBM subtypes in a GBM sample via a pathway -based classifier approach and administering to the subject a pharmaceutically effective amount of an agent capable of modifying the activity of the biological pathways associated with the one or more GBM subtypes.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
22.
POINT-OF-CARE MICROSCOPE FOR REAL-TIME ACQUISITION OF VOLUMETRIC HISTOLOGICAL IMAGES IN VIVO
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Hillman, Elizabeth M.C.
Patel, Kripa B.
Liang, Wenxuan
Abstract
A microscope routes excitation light through a first set of optical components so the excitation light is projected into a sample and forms a sheet of excitation light at an oblique angle. The position of the sheet varies depending on an orientation of the scanning element. The first set of optical components routes detection light back to the scanning element, which routes the detection light into a second set of optical components. The second set of optical components forms an intermediate image plane that is imaged onto a detector. In some embodiments, a folding mirror is disposed between the first and second sets of optical components. In some embodiments, an optically transparent spacer covers the first objective and is configured to press against tissue being imaged. This spacer sets the working distance for the first objective to capture a particular range of depths within the tissue.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Sugahara, Kazuki
Lowy, Andrew M.
Abstract
The invention described relates to the newly discovered ability of tumor internalizing arginylglycylaspartic acid (iRGD) peptides to alter the immune cell landscape in pancreatic ductal adenocarcinoma (PDAC) and other cancers. The iRGD peptides sensitize the cancer to immune checkpoint inhibitors, for example anti-PD-L1, anti-PD-L1. anti-PD-1, and anti-CTLA4 monoclonal antibodies to specifically deplete Tregs within the tumor, resulting in expansion of intratumoral CD8+ T cells (effector cells). This provides methods of treating cancers such as PDAC, preferably in synergistic combination with chemotherapy and immunotherapy, which leads to reduced tumor burden and prolonged survival.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
24.
MEMBRANELESS ELECTROLYZERS FOR THE PRODUCTION OF ALKALINE AND ACIDIC EFFLUENT STREAMS
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Van Hinsberg, Quinten
Esposito, Daniel
Abstract
The system includes electrolyzers to generate acidic and alkaline effluent streams from saltwater. The electrolyzer include stacked pairs of porous anodes and cathodes that define feed channels into which reactants, e.g., hydrogen and brine, can be pumped to undergo an oxidation-reduction reaction. The porous cathode carries out the HER to generate H2, which floats upwards to the porous anode, where it is oxidized through the HOR. The reaction can thus progress in a self-maintaining manner. The HER creates an alkaline product stream with increased basicity, and the HOR an acidic product stream with increased acidity, compared to the inlet stream. Streams are pumped through the porous electrodes and the electrolyzer to sweep effluent through separate channels before they can combine. The alkaline product stream can have an alkalinity sufficient to drive metal ion precipitation in raw saltwater prior to feeding to the electrolyzer to reduce fouling/degradation of electrolyzer electrodes.
UNIVERSITY OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCH (Canada)
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (Canada)
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (USA)
Inventor
Clark, Samuel
Cassidy, Clifford
Rosa-Neto, Pedro
Wengler, Kenneth
Horga Hernandez, Guillermo
Abstract
A neuromelanin sensitive magnetic resonance imaging ("MRI") technique, method and computer-accessible medium for measuring the extent of, providing a diagnosis of, monitoring the treatment of, assessing novel treatments for, or determining a prognosis related to one or more neurological conditions.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Belvedere, Sandro
Lin, Hua Viola
Devita, Robert J.
Turcotte, Stephane
Johnstone, Shawn
Abstract
The disclosure provides FOXO1 inhibitors having beneficial properties such as selectivity and metabolic stability. FOXO1 inhibitors are useful in the treatment of diabetes.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
29.
METABOLIC AUGMENTATION TO PROMOTE AND ENHANCE IMMUNE RESPONSE BY TCF1+ T CELL REPOPULATION
A method of treating a condition in a subject by improving the immune response of the subject comprising first determining the level of TCF1 in the subject to identify the subject as having an anti -PD- 1 responder phenotype or an anti-PD-1 non-responder phenotype, then administering an anti-PD-1 treatment to a subject having an anti-PD-1 responder phenotype or a metabolic inhibitor prior to ant-PD-1 treatment to a subject having an anti-PD-1 non/responder phenotype.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Rodenkirch, Charles
Wang, Qi
Abstract
Methods and devices for positioning a nerve stimulation device on a subject are provided. Aspects are directed to methods of positioning a stimulation device on an anatomic target of a subject comprising positioning an alignment guide adjacent to at least a first alignment point associated with the anatomic target on the subject, wherein the alignment guide indicates a first target location on the anatomic target of the subject, and positioning the stimulation device at the first target location.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Sykes, Megan
Hawley, Robert J.
Yamada, Kazuhiko
Sachs, David H.
Abstract
Provided herein are recombinant miniature swine expressing human CD47 in a tissue specific fashion. Also provided are kidneys isolated from a miniature swine, wherein the glomeruli of the kidney express human CD47 at a level higher than the level of human CD47 expression in the tubules of the kidney. Furthermore, provided herein are methods of transplanting such swine kidneys with glomeruli-specific expression of human CD47 from recombinant miniature swine into human recipients. In certain aspects, provided herein are methods of transplantation comprising transplanting hematopoietic stem cells expressing human CD47 from a first donor animal (e.g., a miniature swine) and a kidney expressing human CD47 in the glomeruli from a second donor animal (e.g., a miniature swine) to a recipient (e.g., a human recipient).
A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermen
A61F 13/00 - Bandages or dressings; Absorbent pads
A61K 35/22 - Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
A61N 1/30 - Apparatus for iontophoresis or cataphoresis
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Leong, Kam
Bhansali, Divya
Li, Tianyu
Abstract
The nanoparticulate system for delivering treating agents may be used, for example, for treating inflammation, or for treating cancer, such as oral cancer, and associated inflammation. The system used in this manner provides a solution to oral cancer and its associated metastasis by providing a targeted therapy to deliver chemotherapeutics. The nanoparticulate system is in the form of cholesterol-modified polyamidoamine-G3 nanoparticles (PAMAM-Chol NPs), which are used as a carrier for at least one drug. The at least one drug may include at least one cancer drug, at least one corticosteroid, at least one anabolic steroid, at least one hormone (natural or synthetic), and combinations thereof.
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (USA)
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Hernandez, Guiellermo Horga
Cassidy, Clifford Mills
Wengler, Kenneth
Abstract
The subject matter disclosed herein relates to a method for determining dopamine function in a subject, the method comprising acquiring one or more neuromelanin-Magnetic Resonance Imaging (NM-MRI) scans of the subject's dopamine-associated brain region of interest.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Konofagou, Elisa E.
Burgess, Mark
Ji, Robin
Batts, Alec J.
Abstract
The present subject matter relates to techniques for simultaneous blood-brain barrier opening and cavitation imaging. The disclosed system can include a transducer and a processor. The transducer can be configured to generate a plurality of focused transmits and simultaneously obtain a plurality of power cavitation images. The processor can be configured to control a parameter of the focused transmits, acquire the power cavitation images between each focused transmit, and generate a cavitation map based on the power cavitation images.
BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Disclosed herein is a kit for detecting or quantifying a SARS-CoV-2 nucleocapsid phosphoprotein, including a first antibody, wherein a variable heavy chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 11, 13, 15, 17, 19, and 21, and a variable light chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 12, 14, 16, 18, 20, and 22; and a second antibody, wherein a variable heavy chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 9 and 13, and a variable light hain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 14.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Iavarone, Antonio
Lasorella, Anna
Abstract
The subject matter described herein relates to a method of regulating protein kinase activity by allosteric modifications such as prolyl hydroxylation.
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups
C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
Disclosed herein are engineered heterodimer or heterotrimer proteins which use a non- naturally occurring polypeptide domain comprising 1 -5 alpha helices connected by amino acid linkers and an IgG2 hinge domain either alone or in conjunction with an IgG2 Fc domain. The heterodimer and heterotrimer proteins can further comprise an antigen-binding fragment that binds a lineage-specific cell-surface antigen, a polypeptide that binds to a molecule expressed on an immune cell (e.g., natural killer cell) and/or a polypeptide that binds to a molecule expressed on another type of immune cell (e.g., T cells). Also disclosed herein are nucleic acids encoding the proteins, vectors comprising the nucleic acids, compositions, and methods of treatment.
A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
39.
METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA WITH FENOTEROL HYDROBROMIDE, A .BETA.2-ADRENERGIC RECEPTOR AGONIST, AND DERIVATIVES THEREOF
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Tkatchenko, Andrei V.
Tkatchenko, Tatiana V.
Abstract
The disclosure relates to methods and compositions for preventing and/or treating an ocular disease. In particular, the disclosure relates to preventing and/or treating myopia with systemic or topical administration of fenoterol hydrobromide, which is a ?2-adrenergic receptor agonist, or a derivative thereof.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Tkatchenko, Andrei V.
Tkatchenko, Tatiana V.
Abstract
The disclosure relates to methods and compositions for preventing and/or treating an ocular disease. In particular, the disclosure relates to preventing and/or treating myopia with systemic or topical administration of trichostatin A, which is a histone deacetylase (HD AC) inhibitor, or a derivative thereof.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Tkatchenko, Andrei V.
Tkatchenko, Tatiana V.
Abstract
The disclosure relates to methods and compositions for preventing and/or treating an ocular disease. In particular, the disclosure relates to preventing and/or treating myopia with systemic or topical administration of fingolimod phosphate, which is a sphingosine-1- phosphate receptor modulator, or a derivative thereof.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Tkatchenko, Andrei V.
Tkatchenko, Tatiana V.
Abstract
The disclosure relates to methods and compositions for preventing and/or treating an ocular disease. In particular, the disclosure relates to preventing and/or treating myopia with systemic or topical administration of berberine chloride, which is a berberidaceaen alkaloid, or a derivative thereof.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
43.
METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA WITH S-METHYL-L-THIOCITRULLINE, A SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE (NNOS) INHIBITOR, AND DERIVATIVES THEREOF
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Tkatchenko, Andrei V.
Tkatchenko, Tatiana V.
Abstract
. The disclosure relates to methods and compositions for preventing and/or treating an ocular disease. In particular, the disclosure relates to preventing and/or treating myopia with systemic or topical administration of S-methyl-L-thiocitrulline hydrochloride, which is a selective neuronal nitric oxide synthase (nNOS) inhibitor, or a derivative thereof.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Mukherjee, Siddhartha
Borot, Florence
Ali, Abdullah Mahmood
Abstract
Disclosed herein are methods of administering an agent targeting a lineage- specific cell-surface antigen, e.g., CD33 or EMR2, and a population of hematopoietic cells that are altered in the expression of the lineage- specific cell- surface antigen, e.g., CD33 or EMR2, for immunotherapy of hematological malignancies. Also disclosed herein are methods of administering an agent targeting more than one lineage-specific cell- surface antigen, and a population of hematopoietic cells that are altered in the expression of more than one lineage- specific cell-surface antigen, for immunotherapy of hematological malignancies. Cells comprising mutations in CD33, or EMR2, or more than one lineage- specific cell-surface antigen are also provided, as are methods of producing such cells using CRISPR-based base editor systems.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Tkatchenko, Andrei V.
Tkatchenko, Tatiana V.
Abstract
The disclosure relates to methods and compositions for preventing and/or treating an ocular disease. In particular, the disclosure relates to preventing and/or treating myopia with systemic or topical administration of levocabastine hydrochloride, which is a selective histamine HI -receptor antagonist, or a derivative thereof.
A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
C07C 255/60 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
46.
POTENT NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2, GENERATION AND USES THEREOF
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Ho, David D.
Huang, Yaoxing
Liu, Lihong
Nair, Manoj S.
Wang, Pengfei
Yu, Jian
Luo, Yang
Abstract
The subject matter described herein relates to potent monoclonal and bispecific antibodies capable of neutralizing a SARS-CoV-2 viruses and methods of generating the antibodies.
Described herein is a composition and method of treating COVID-19 with lipid- peptide fusion antiviral therapy. Also described is a composition and method of treating Ebola with lipid-peptide fusion antiviral therapy.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
WILLIAM MARSH RICE UNIVERSITY (USA)
Inventor
Karsenty, Gerard
Berger, Julian
Xiao, Han
Abstract
Exemplary methods, compositions and uses thereof can be provided for preventing, reducing and/or treating loss of muscle function. In particular, e.g., it is possible to administer to a subject a pharmaceutical composition comprising a therapeutically effective amount of an agent that enhances Interleukin-6 (IL) release during exercise, and optionally a pharmaceutically acceptable carrier or excipient.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Deckelbaum, Richard J.
Chang, Chuchun Liz
Zirpoli, Hylde
Abstract
The present invention provides compositions and methods involving stable omega-3 diglyceride oil-in-water emulsions for acute therapy to treat and/or prevent tissue or organ injury. The compositions provide protection from cellular death, and find use in patients in need of neuroprotection. For example, the compositions find use in treating ischemia reperfusion injuries, such as ischemic stroke. The compositions further find use for treatment of traumatic injuries, such as traumatic brain injury or spinal cord injury, among others. The compositions have a large time window by which they are effective after onset of traumatic or ischemic injury (e.g., after onset of stroke), and may be administered in conjunction with other therapies.
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
50.
BIODEGRADABLE TEXTILE FIBERS WITH INHERENT COLOR AND PROPERTIES
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Schiros, Theanne
Lee, Chui Lian
Gomez, Valentina
Katterman, Morgana
Lu, Helen H.
Obermeyer, Allie
Brudnicki, Philip
Cocioba, Sebastian S.
Mosher, Christopher Z.
Antrobus, Romare M.
Zhu, Yuncan
Sharma, Aditi
Abstract
A biopolymer composition can be formed based, at least in part, on a recombinantly expressed protein, expressed from a DNA coding sequence of a source protein, and the recombinantly expressed protein can optionally comprise one or more tags that enhance the crosslinking capacity of the protein. It was determined that such biopolymer composition can be suitable for use to obtain, for example, a biodegradable textile that exhibits a functional characteristic associated with the recombinantly expressed protein.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Stockwell, Brent R.
Liu, Hengrui
Forouhar, Farhad
Wang, Qian
Abstract
The present disclosure provides, inter alia, compounds to modulate GPX4 activity. Also provided are pharmaceutical compositions containing same compounds. Further provided are methods for treating or ameliorating the effects of a cancer in a subject, methods of modulating GPX activity in a subject, methods of inducing ferroptosis in a cell, and methods for treating or ameliorating the effects of a cancer in a subject using the compounds or composition in combination with other therapeutic agents.
A61K 31/473 - Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 15/08 - Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 277/54 - Nitrogen and either oxygen or sulfur atoms
C07D 295/192 - Radicals derived from carboxylic acids from aromatic carboxylic acids
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 455/02 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Tsang, Stephen H.
Cui, Xuan
Wang, Nan-Kai
Liu, Pei-Kang
Abstract
The present disclosure relates to methods and compounds for reprogramming metabolism in one specific retinal and neuronal cell type leading to improved cell and tissue survival and function. In particular, the present disclosure relates to increasing PGC1?/Pgcl? or NRF2/Nrf2 or inhibiting HIF/Hif or KEAP1/Keap1 to reprogram metabolism and survival of cells in a variety of neurodegenerative conditions, and specifically those which cause blindness.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Kanner, Scott
Colecraft, Henry M.
Abstract
The present disclosure provides, inter alia, bivalent nanobody molecules and methods for treating or ameliorating the effects of a disease, such as long QT syndrome, or cystic fibrosis, in a subject, using the bivalent nanobody molecules disclosed herein. Also provided are methods of identifying and preparing nanobody binders that target proteins of interest.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
54.
POLYOXAZOLINE MODIFICATIONS MITIGATE STRUCTURAL DEGENERATION OF BIOPROSTHETIC HEART VALVES
A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61K 31/00 - Medicinal preparations containing organic active ingredients
55.
ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS
C07C 225/20 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 295/104 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
56.
STABILIZATION OF RETROMER FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
CORNELL UNIVERSITY (USA)
MEIRAGTX UK II LIMITED (United Kingdom)
THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (USA)
Inventor
Small, Scott A.
Petsko, Gregory
Qureshi, Yasir H.
Waksal, Samuel D.
Forbes, Alexandria
Cox, Rebecca
Abstract
The present disclosure relates to methods and compositions for elevating and stabilizing retromer for treating and/or preventing Alzheimer's disease and other neurodegenerative disorders. Additionally, the disclosure relates to adenoviral based therapy for treating Alzheimer's disease (AD), and other neurodegenerative conditions such as Parkinson's Disease (PD), neuronal ceroid lipofuscinosis (NCL), and transmissible spongiform encephalopathies (TSEs or prion disease), multiple system atrophy (MSA), Down's syndrome, and hereditary spastic paraplegia, as well as tauopathies such as progressive supranuclear palsy (PSP), frontotemporal lobar dementia linked to chromosome 17q21-22 and its subtypes (FTLD-17/FTLD-Tau), Lewy Body Disease (LBD), amyotrophic lateral sclerosis (AES), frontal-temporal degeneration (FTD), ALS-FTD, and chronic traumatic encephalopathy (CTE).
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Sykes, Megan
Hawley, Robert J.
Abstract
The present disclosure provides for transgenic swine, comprising one or more nucleotide sequences encoding one or more HLA I polypeptides and/or one or more HLA II polypeptides inserted into one or more native SLA loci of the swine genome, methods of making and methods of using. The present disclosure also provides for improved methods of making human immune system mice.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (USA)
Inventor
Clark, Samuel
Horga Hernandez, Guillermo
Cassidy, Clifford Mills
Wengler, Kenneth
Abstract
A neuromelanin sensitive magnetic resonance imaging ("MRI") technique, method and computer-accessible medium for measuring the extent of, providing a diagnosis of, monitoring the treatment of, assessing novel treatments for, or determining a prognosis related to Parkinson's disease.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
SENECA THERAPEUTICS, INC. (USA)
Inventor
Racaniello, Vincent R.
Rosenfeld, Amy B.
Hallenbeck, Paul L.
Abstract
Provided herein are compositions and methods of using Seneca Valley Virus (SVV) or a derivative thereof and an interferon type I (IFN-I) inhibiting agent comprising an mTOR inhibitor for treating a cancer in a subject. The disclosed methods particularly rely upon the expression level of an ANTXR1 and the expression level of IFN-I in the cancer from the subject. Also provided herein are methods for predicting the efficacy of an SVV treatment comprising IFN-I inhibiting agent.
The present disclosure provides, inter alia, improved PNA agents, compositions comprising the same, and methods for treating diseases such as cancers by using such agents and / or compositions. Methods for reducing expression of a gene in a cell are also provided.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Duvall, Jacquelyn
Thompson, Brandon
Sims, Peter Alan
Yuan, Jinzhou
Liu, Zhouzerui
Mizrak, Dogukan
Gebhart, Steven C.
Boone, Peter Glyn
Abstract
Systems and methods for associating single cell imaging data with RNA transcriptomics. Single cells are isolated into microwells with a microbead having oligonucleotides conjugated on its surface. Each oligonucleotide includes a cell identifying optical barcode that is unique to that bead and binding sequence for RNA capture after cell lysis. The system is configured for loading single cells into the microarray and for flowing cell lysis buffers and other reagents into the microarray for performing RNA library sample preparation. The system is also configured for lowing optical hybridization probes that are complementary to the cell identifying optical barcodes and optically labeled onto the microwell array and for obtaining images of the microwells in response to the probes. The system and unique cell identifying optical barcodes and complementary optical hybridization probes facilitate a link between phenotypic imaging of cells resident on the microwell array with single cell whole transcriptome sequencing.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Sommer, Morten Otto Alexander
Bongers, Mareike
Wang, Harris He
Cusimano, Frank
Abstract
The invention provides a composition for use as a medicament, comprising cells of a recombinant microorganism capable of producing increased amounts of one or more of 5-hydroxytryptophan (5-HTP), 5-hydroxytryptamine (5-HT) and tryptamine (TRM) as compared to the non-recombinant microorganism from which it was derived. The composition finds use in preventing and/or treating TRM-; 5-HTP-, or 5-HT-related disorders of the central nerve system (CNS); enteric nervous system (ENS); gastro intestine (GI) and metabolism in a mammal, and may be orally administered to a mammal in need thereof. Additionally, a composition comprising cells of a recombinant microorganism capable of producing melatonin is provided for use as a medicament, such as for treatment of depression, dementia, cancer and sleep disorder.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Wang, Qi
Rodenkirch, Charles
Abstract
Methods and devices for modifying sensory processing in a subject are provided. Aspects are directed to applying tonic vagus nerve stimulation to a subject for transient sensory processing modification. Devices for applying tonic vagus nerve stimulation when a subject is in need of sensory modification or on demand are also provided. The devices can be coupled with a prosthetic device for application to regions of the body in need of vagus nerve stimulation.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
BARNARD COLLEGE (USA)
Inventor
Sigfusson, Bergur
Gunnlaugsson, Einar
Sigurdardottir, Holmfridur
Gislason, Sigurdur Reynir
Oelkers, Eric H.
Snaebjornsdottir, Sandra Osk
Galeczka, Iwona M.
Wolff-Boenisch, Domenik
Stefansson, Andri
Clark, Deirdre Elizabeth
Aradottir, Edda Sif Pind
Gunnarsson, Ingvi
Arnarson, Magnus Por
Sighvatsson, Huni
Mesfin, Kiflom G.
Alfredsson, Helgi A.
Jonsson, Porsteinn
Matter, Jurg
Stute, Martin
Voigt, Martin Johannes
Abstract
This invention relates to a method and a system of abating carbon dioxide (CO2) and/or hydrogen sulfide (H2S) in a geological reservoir. Water is pumped or transferred from a water source to an injection well. The gasses are merged with the water under conditions where the hydraulic pressure of the water is less or equal to the pressure of CO2 and/or H2S gas at the merging point. The water with dissolved CO2 and/or H2S is transfen-ed further downwardly with at a certain velocity, whereafter the dissolved CO2 and/or H2S is injected into the geological (e.g. geothermal) reservoir.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (USA)
UNIVERSITE PARIS-SACLAY (France)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France)
Inventor
Denny, Christine A.
Gardier, Alain M.
David, Denis J.
Mendez-David, Indira
Faye, Charlene
Chen, Briana K.
Abstract
Methods for prophylactically treating a stress-induced affective disorder or stress-induced psychopathology in a subject are provided. Also provided are methods for inducing and/or enhancing stress resilience in a subject. In certain embodiments, an effective amount of an agonist of the serotonin 4 receptor (5-HT4R), or a pharmaceutically acceptable salt or derivative thereof, is administered to a subject prior to a stressor.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Gras Pena, Rafael
Sykes, Megan
Danzl, Nichole
Khosravi-Maharlooei, Mohsen
Abstract
The current disclosure provides for methods of promoting differentiation of pluripotent stem cells into thymic epithelial cells or thymic epithelial cell progenitors as well as the cells obtained from the methods, and solutions, compositions, and pharmaceutical compositions comprising such cells. The current disclosure also provides for methods of using the thymic epithelial cells or thymic epithelial cell progenitors for treatment and prevention of disease, generating organs, as well as other uses, and kits.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Xu, Xiaoming
Deng, Shi-Xian
Landry, Donald, W.
Devita, Robert, J.
Lin, Hua, V.
Lee, Yunkyoung
Accili, Domenico
Belvedere, Sandro
Abstract
Various embodiments relate to a compound (represented by Formula I) or a pharmaceutically acceptable salt or tautomer thereof. The compound may selectively inhibit a Forkhead Box O1 (FOXO1) transcription factor. Various embodiments relate to methods comprising administering to a mammal having a disease or disorder associated with impaired pancreatic endocrine function, a therapeutically effective amount of the compound or a pharmaceutically acceptable salt or tautomer thereof. Various embodiments relate to methods for producing enteroendocrine cells that make and secrete insulin in a mammal, comprising administering to the mammal an effective amount of the compound or a pharmaceutically acceptable salt or tautomer thereof.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
THE TRUSTEES OF COLUMIBA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Vaughan, John Thomas, Jr.
Geethanath, Sairam
He, Peidong
Abstract
An exemplary system, method, and computer-accessible medium for generating a Cartesian equivalent image(s) of a portion(s) of a patient(s), can include, for example, receiving non-Cartesian sample information based on a magnetic resonance imaging (MRI) procedure of the portion(s) of the patient(s), and automatically generating the Cartesian equivalent image(s) from the non-Cartesian sample information using a deep learning procedure(s). The non-Cartesian sample information can be Fourier domain information. The non-Cartesian sample information can be undersampled non-Cartesian sample information. The MRI procedure can include an ultra-short echo time (UTE) pulse sequence. The UTE pulse sequence can include a delay(s) and a spoiling gradient. The Cartesian equivalent image(s) can be generated by reconstructing the Cartesian equivalent image(s). The Cartesian equivalent image(s) can be reconstructed using a sampling density compensation with a tapering of over a particular percentage of a radius of a k-space, where the particular percentage can be about 50%.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Vaughan, Jr, John Thomas
Geethanath, Sairam
Jambawalikar, Sachin R.
Poojar, Pavan
Qian, Enlin
Abstract
An exemplary system, method, and computer-accessible medium for generating a particular image which can be a quantitative image(s) of at least one section(s) of a patient(s) or (ii) a non-synthetic contrast image(s) of the section(s) of the patient(s), can include, for example, generating a first magnetic resonance (MR) signal and directing the first MR signal to patient(s), receiving a second MR signal from the patient(s) that can be based on the first MR signal, and generating the particular image(s) based on the second MR signal. The first MR signal can be a configured MR signal. The configured MR signal can be configured for a particular contrast. The first MR signal can have a constant signal intensity. The first MR signal can be generated based on a degree of a plurality of flip angles that maintains the constant signal intensity. A degree of flip angles can be selected for the first MR signal based on the particular contrast
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Fojo, Antonio Tito
Deng, Shi-Xian
Landry, Donald W.
Bates, Susan E.
Xu, Xiaoming
Abstract
The present disclosure provides conjugate compositions comprising non-hydrolyzable, non-cleavable, stable linkers, a targeting moiety, and a therapeutic or chemotherapeutic agent. More specifically the present disclosure provides for compositions comprising non- hydrolyzable, non-cleavable, stable linkers, a somatostatin receptor (SSTR) targeting moiety, such as lanreotide, and a chemotherapeutic agent targeting microtubules, such as mertansine. Methods of using the compositions to treat cancer and other diseases are also provided.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Sternberg, Samuel Henry
Klompe, Sanne Eveline
Vo, Phuc Hong
Abstract
In certain embodiments, the present systems and methods use Tn7-like transposons that encode CRISPR-Cas systems for programmable, RNA-guided DNA integration. For example, the CRISPR-Cas machinery directs the Tn7 transposon-associated proteins to integrate DNA downstream of a target site (e.g., a genomic target site) recognized by a guide RNA (gRNA).
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
72.
HISTONE ACETYLTRANSFERASE MODULATORS AND COMPOSITIONS AND USES THEREOF
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
APPIA PHARMACEUTICALS LLC (USA)
Inventor
De Vries, Luuk Elard
Zuccarello, Elisa
Calcagno, Elisa
Landry, Donald W.
Deng, Shixian
Fiorito, Jole
Arancio, Ottavio
Yarnold, Christopher John
Jones, Richard Scott
Rowley, Julian Hugh
Abstract
Compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.
C07C 235/64 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (USA)
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (USA)
Inventor
Kruegel, Andrew C.
Sames, Dalibor
Javitch, Jonathan A.
Majumdar, Susruta
Abstract
The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and methods of using the compound to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorder, and opioid withdrawal symptoms.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61P 25/00 - Drugs for disorders of the nervous system
C07D 459/00 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone
74.
COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC ANTIGENS
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Mukherjee, Siddhartha
Borot, Florence
Ali, Abdullah, Mahmood
Abstract
Disclosed herein are methods of administering an agent targeting a lineage-specific cell- surface antigen, e.g., CD33, and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen, e.g., CD33 for immunotherapy of hematological malignancies. Cells comprising mutations in CD33 are also provided, as are gRNAs targeting CD33.
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
75.
SYSTEM, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR NEUROMELANIN-SENSITIVE MAGNETIC RESONANCE IMAGING AS A NON-INVASIVE PROXY MEASURE OF DOPAMINE FUNCTION IN THE HUMAN BRAIN
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (USA)
Inventor
Hernandez, Guillermo Horga
Cassidy, Clifford Mills
Abstract
[00144] An exemplary system, method and computer-accessible medium for determining a dopamine function of a patient(s) can include, for example, receiving imaging information of a brain of the patient(s), determining a Neuromelanin (NM) concentration of the patient(s) based on the imaging information, and determining the dopamine function based on the NM concentration. The NM concentration can be determined using a voxel-wise analysis procedure. The voxel-wise analysis procedure can be used to determine a topographical pattern(s) within a substantia nigra (SN) of the brain of the patient(s). The topographical pattern(s) can include a pattern(s) of cell loss in the SN. The NM concentration can be based on a NM loss in the brain of the patient(s).
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Sykes, Megan
Khosravi-Maharlooei, Mohsen
Danzl, Nichole
Abstract
The present disclosure relates to making a hybrid pig-human thymic tissue and using the hybrid thymic tissue to induce tolerance in xenotransplantation. The hybrid thymic tissue can also be used for restoring or inducing immunocompetence in a recipient as well as restoring or promoting thymus-dependent ability for T cell progenitors to develop into mature functional T cells in a recipient.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Weetall, Marla L.
Cao, Liangxian
Davis, Thomas W.
Dumble, Melissa L.
Eberle-Singh, Jaime A.
Olive, Kenneth P.
Abstract
A method for treating pancreatic cancer in a subject in need thereof comprising, administering to the subject an effective amount of a tubulin polymerization inhibitor compound is described herein. More particularly, a method for treating pancreatic ductal adenocarcinoma in a subject in need thereof comprising, administering to the subject an effective amount of a substituted reverse pyrimidine tubulin polymerization inhibitor compound alone or in combination with other chemo-therapeutic agents is described herein.
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Sahin, Ozgur
Schenker, Eran
Ungar, Yocheved
Cakmak, Onur
Abstract
Systems and methods for developing a composite material are disclosed. The system can include a plurality of particles and a plurality of filaments. The plurality of particles can generate mechanical force in response to changing relative humidity, and the plurality of filaments can transfer the mechanical force throughout the composite material.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Geethanath, Sairam
Vanguri, Rami
Jambawalikar, Sachin R.
Vaughan, Jr., John Thomas
Abstract
Exemplary system, method, and computer-accessible medium for generating a magnetic resonance (MR) tissue fingerprint training network(s) can be provided, using which it is possible to, for example, receive first information related to a MR image(s) of a portion(s) of a phantom(s), partition the first information into a plurality of patches, and generate the MR tissue fingerprint training network(s) by applying a convolutional neural network(s) to the patches. The convolutional neural network(s) can be a fully convolutional neural network(s). Each of the patches can be a same size. The patches can be overlapping patches. A size of the patches can be 3x3 pixels. The MR tissue fingerprint training network can be generated based on float values for each of the patches.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Geethanath, Sairam
Sravan Ravi, Keerthi
Vaughan, Jr., John Thomas
Abstract
Exemplary system, method and computer-accessible medium for remotely initiating a medical imaging scan(s) of a patient(s), can include, for example, receiving, over a network, encrypted first information related to first parameters of the patient(s), determining second information related to image acquisition second parameters based on the first information, generating an imaging sequence(s) based on the second information, and initiating, remotely from the patient(s), the medical imaging scan(s) based on the imaging sequence(s). The medical imaging scan(s) can be a magnetic resonance imaging ("MRI") sequence(s). The image acquisition second parameters can be MRI acquisition parameters, and the imaging sequence(s) can be a gradient recalled echo ("GRE") pulse sequence(s).
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Cantley, Lewis C.
Hopkins, Benjamin
Mukherjee, Siddhartha
Goncalves, Marcus
Abstract
Described herein are compositions and methods for treating a disease or disorder associated with PI3K signaling. For example, such compositions can include use of modulators of glucose metabolism, use of at least one kinase in the insulin-receptor/PI3K/AKT/mTOR pathway, and/or use of diet that influences the subject's metabolic state.
THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (USA)
Inventor
Hirano, Michio
Akman, Hasan O.
Lopez-Gomez, Carlos
Abstract
The invention relates generally to a method of treatment for a human genetic disease, such as diseases characterized by unbalanced nucleotide pools, e.g., mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency, using gene therapy. The gene therapy may involve administration of one or more constructs, such as a viral vector, containing a nucleic acid encoding a functional protein. The functional protein may correspond to a nuclear gene. For treatment of TK2 deficiency, the gene therapy may involve administration of one or more constructs, such as a viral vector, containing a nucleic acid encoding a functional TK2 enzyme. The treatment may also involve the administration of pharmacological therapy in conjunction with the gene therapy. The treatment protocols of the disclosure, such as those involving gene therapy alone or in combination with pharmacological therapy, can be used to treat, prevent, and/or cure various other disorders of unbalanced nucleoside pools, especially those found in mitochondrial DNA depletion syndrome.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Stockwell, Brent R.
Wichterle, Hynek
Bos, Pieter
Zask, Arie
Thams, Sebastian
Lowry, Emily Rhodes
Abstract
The present invention provides, inter alia, a compound having the structure (I). Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present invention. Further provided are methods for treating or ameliorating the effects of a disorder in a subject, methods of suppressing the toxicity of endoplasmic reticulum (ER) stress in a subject, methods of treating or ameliorating the effects of a disease involving axon degeneration in a subject, and methods for treating or ameliorating the effects of a neurodegenerative disease.
C07D 209/20 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
C07D 401/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
84.
FORCE SENSOR CLEAVAGE DOMAIN CONTAINING CHIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Choe, Joseph H.
Langridge, Paul
Lim, Wendell A.
Roybal, Kole T.
Struhl, Gary
Abstract
Provided are chimeric polypeptides which modulate various cellular processes following cleavage of a force sensor cleavage domain, including non-Notch force sensor cleavage domains, induced upon binding of a specific binding member of the chimeric polypeptide with its binding partner. Methods of using force sensor cleavage domain-containing chimeric polypeptides to modulate cellular functions, including e.g., modulation (including induction or repression) of gene expression, are also provided. Nucleic acids encoding the subject chimeric polypeptides and associated expression cassettes and vectors as well as cells that contain such nucleic acids and/or expression cassettes and vectors are provided. Also provided, are methods of monitoring cell-cell signaling and method of treating a subject using the described components, as well as kits for practicing the subject methods.
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Nuckolls, Colin
Hernandez Sanchez, Raul
Yang, Yuan
Sisto, Thomas
Cheng, Qian
Milton, Margarita
Abstract
The present disclosure relates to organic electrolyte solutions including organic electrolytes (e.g., aromatic imides, ferrocenes, spiro fused compounds, or cyclopropenium compounds), and redox flow batteries and systems including the same.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Lentzsch, Suzanne
Abstract
Methods and pharmaceutical compositions for treatment of amyloid deposition diseases using chimeric (e.g., mouse- human) antibody are disclosed, including a method for treating amyloid deposition diseases with cardiac involvement by administering pharmaceutical compositions comprising a chimeric anti-amyloid fibril antibody. The methods herein can improve myocardial function in patients diagnosed with light chain amyloid light chain amyloidosis (ALA) having a cardiac involvement in as little as three weeks after treatment.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Jones, Tarran
Levy, Alison
O'Brien, Siobhan
Abstract
A chimeric mouse-human antibody for treatment of amyloid deposition diseases, pharmaceutical compositions comprising the antibody, methods and materials for producing the antibody, and methods for treating an amyloid deposition disease using the antibody and the pharmaceutical composition.
A61K 51/10 - Antibodies or immunoglobulins; Fragments thereof
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Yu, Nanfang
Overvig, Adam
Shrestha, Sajan
Abstract
Techniques for creating a replacement for optical elements with diffractive planar components based on metasurfaces are provided. In one example, a substantially flat optical component for lensing incoming electromagnetic radiation having at least one wavelength and a first phase into outgoing electromagnetic radiation having a second phase is provided.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Wobma, Holly
Kanai, Mariko
Vunjak-Novakovic, Gordana
Abstract
The present disclosure describes immunosuppressive mesenchymal stromal cells and exosomes secreted from immunosuppressive mesenchymal stromal cells, and methods for their preparation. The disclosure also describes methods for treating subjects or preventing subjects at risk for conditions by administering the immunosuppressive mesenchymal stromal cells or secreted exosomes. The present disclosure also describes kits for preparing immunosuppressive mesenchymal stromal cells and exosomes secreted from immunosuppressive mesenchymal stromal cells.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Arnold, Alexander E.
Stafford, Douglas C.
Cook, James M.
Emala, Charles W.
Forkuo, Gloria
Jahan, Rajwana
Kodali, Revathi
Li, Guanguan
Stephen, Michael Rajesh
Abstract
Pyrrolobenzodiazepines target alpha-4 and alpha-5 GABAA receptors for use in the treatment of airway hyperresponsiveness and inflammation in asthma. Compounds selectively partition to the peripheral compartment and have reduced CNS effects.
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61P 11/00 - Drugs for disorders of the respiratory system
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
O'Connor, Owen Anthony
Deng, Shi Xian
Scotto, Luigi
Purgatorio, Rosa
Arancio, Ottavio
Fiorito, Jole
Amengual, Jennifer Effie
Landry, Donald W.
Abstract
The invention provides pharmaceutical compositions and methods for treating cancer by administering a HAT modulator and a HDAC modulator to a subject. HAT modulators may be of formula (I),
C07C 235/64 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Bacchetta, Matthew
Chicotka, Scott
Fung, Kenmond
Guenthart, Brandon
O'Neill, John
Vunjak-Novakovic, Gordana
Abstract
Described are systems, methods, and devices relating to normothermic extracorporeal support of an organ, tissue, or bioengineered graft comprising cross-circulation (XC) perfusion for prolonged periods (days to weeks) via an XC perfusion circuit in connection with an extracorporeal host (e.g., animal, patient, organ transplant recipient) are disclosed. The XC perfusion circuit comprises auto-regulation of blood flow based on the trans-organ blood pressure difference between arterial and venous pressure. Recipient support enabled 36 h of normothermic perfusion that maintained healthy lungs with no significant changes in physiologic parameters and allowed for the recovery of injured lungs. Extended support enabled multiscale therapeutic interventions in all extracorporeal lungs. Lungs exceeded transplantation criteria.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Wasmuth, Andrew
Landry, Donald W.
Abstract
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.
A61K 31/5025 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/00 - Drugs for disorders of the nervous system
C07C 215/10 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
C07C 229/24 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
C07C 279/26 - X and Y being nitrogen atoms, i.e. biguanides
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
ACADIA PHARMACEUTICALS INC. (USA)
Inventor
Burnett, Lisa Cole
Egli, Dieter
Leibel, Rudolph L.
Cotter, Sara
Abstract
The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).
A61K 31/221 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Stojanovic, Milan
Yang, Kyungae
Taylor, Steven
Milosavic, Nenad
Abstract
The present invention relates to aptamer-based assays to capture and/or detect analytes comprising primary and secondary aptamers, as well as compositions comprising such primary and secondary aptamers, wherein analytes comprise small molecules that offer limited mutually non-competitive epitopes to antibodies, that is, with limited ability to measure in non-competitive sandwich assays using primary and secondary antibodies or primary and secondary aptamers.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventor
Cohen, Ira S.
Brink, Peter R.
Rosen, Michael R.
Abstract
A method of treating cancer in vivo includes introducing in vitro into human mesenchymal stem cells (hMSCs) at least one type of inhibitory oligonucleotide, and contacting a tumor tissue of syncytial cancer cells with the hMSCs in vivo under conditions permitting a hMSC to form a gap junction channel with a first syncytial cancer cell of the tumor tissue. As a result, the at least one type of inhibitory oligonucleotide is delivered into the first syncytial cancer cell by traversing the gap junction channel and the at least one type of inhibitory oligonucleotide is delivered into a second syncytial cancer cell of the tumor tissue by traversing a gap junction channel between the first syncytial cancer cell and the second syncytial cancer cell.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Lavarone, Antonio
Lasorella, Ann
Abstract
The present disclosure provides, in one embodiment, a method of treating or preventing an ID2 protein-related disease in a patient at risk of developing or having such a disease by administering to the patient a composition in an amount and for a time sufficient to increase degradation of HIFa in a cell affected by the ID2 protein-related disease in the patent and/or to decrease half-life of HIFa in the cell affected by the ID2 protein-related disease in the patient, as compared to an untreated cell affected by the ID2 protein-related disease.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Kwong, Peter
Kwon, Young Do
Georgiev, Ivelin
Ofek, Gilad
Zhang, Baoshan
Mckee, Krisha
Mascola, John
Chuang, Gwo-Yu
O'Dell, Sijy
Gindin, Tatyana
Shapiro, Lawrence
Bailer, Robert
Louder, Mark
Asokan, Mangaiarkarasi
Schwartz, Richard
Cooper, Jonathan
Carlton, Kevin
Bender, Michael
Connors, Mark
Pegu, Amarendra
Kueltzo, Lisa
Abstract
Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Mukherjee, Siddhartha
Mahmood Ali, Abdullah
Borot, Florence
Abstract
Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Kruegel, Andrew
Sames, Dalibor
Wulf, Madalee G.
Javitch, Jonathan A.
Abstract
The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, a method of producing the compound, pharmaceutical compositions comprising the compound and a pharmaceutical carrier for activating the mu or delta opioid receptor for use in treating a subject afflicted with neurological or psychiatric diseases. The present invention also provides combinations of the compound or a pharmaceutical composition of the compound with a second agent for use in treating neurological and psychiatric diseases.
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A61P 25/00 - Drugs for disorders of the nervous system